Split History
ETFs Holding PLX »    PLX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx® protein expression system. Co.'s commercial product, taliglucerase alfa for injection is an enzyme replacement therapy for the long-term treatment of adult patients with a diagnosis of type 1 Gaucher disease, which is marketed under the name Elelyso in other territories. Co.'s product pipeline includes, among other candidates: PRX-102, for the treatment of Fabry disease; PRX-110, for the treatment of cystic fibrosis, to be administered by inhalation; and OPRX-106, Co.'s oral antiTNF (Tumor, Necrosis Factor) product candidate. According to our PLX split history records, Protalix BioTherapeutics has had 2 splits.
PLX split history picture
Protalix BioTherapeutics (PLX) has 2 splits in our PLX split history database. The first split for PLX took place on December 05, 1991. This was a 4 for 3 split, meaning for each 3 shares of PLX owned pre-split, the shareholder now owned 4 shares. For example, a 1000 share position pre-split, became a 1333.33333333333 share position following the split. PLX's second split took place on August 14, 1992. This was a 3 for 2 split, meaning for each 2 shares of PLX owned pre-split, the shareholder now owned 3 shares. For example, a 1333.33333333333 share position pre-split, became a 2000 share position following the split.

When a company such as Protalix BioTherapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the PLX split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protalix BioTherapeutics shares, starting with a $10,000 purchase of PLX, presented on a split-history-adjusted basis factoring in the complete PLX split history. PLX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/24/2009
End date: 06/21/2019
Start price/share: $3.75
End price/share: $0.41
Dividends collected/share: $0.00
Total return: -89.07%
Average Annual Total Return: -19.86%
Starting investment: $10,000.00
Ending investment: $1,093.34
Years: 10.00
Date Ratio
12/05/19914 for 3
08/14/19923 for 2
PLX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

PLXP Split History
PMD Split History
PPHM Split History
PRAN Split History
PRGO Split History
PRPO Split History
PRSN Split History
PRTK Split History
PRXL Split History
PSTI Split History

Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
Northern Technologies International Corporation (NTIC)
Digirad Corporation (DRAD)
Hemispherx Biopharma, Inc. (HEB)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

PLX Insider Buying

PLX Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.